8-K: Bespoke Extracts Achieves Record Q3 2025 Results

Bespoke Extracts, operating as The Joint Company, reported record Q3 2025 revenue and improved net loss, driven by increased pre-roll production and margin expansion in Colorado.

Summary

• Record Revenue: $467,945 in Q3 2025, up 19.8% from Q2 2025 and 68.6% year-over-year.
• Gross Margin: 50.0% in Q3 2025, an 860 basis point increase from Q3 2024.
• Net Loss Improvement: GAAP net loss narrowed to $78,088, a 72% improvement from Q3 2024.
• Record Production: 209,600 pre-rolls produced during the quarter, up 81% year-over-year.
• Nine-month revenue for 2025 reached $1,121,657, a 37.4% increase from the prior year.
• Nine-month net loss for 2025 improved to $(543,715), a 36.1% reduction from the prior year.

Sentiment

Score: 8

Explanation: The company reported record revenue, significant gross margin expansion, and a substantial reduction in net loss, demonstrating strong operational execution in a challenging market. Management commentary is highly optimistic about future growth and scalability. However, the company still operates at a net loss and has a significant stockholders' deficit and current liabilities exceeding current assets, which tempers the overall sentiment slightly.

Positives

• Record quarterly revenue of $467,945, showing significant growth both quarter-over-quarter (19.8%) and year-over-year (68.6%).
• Strong gross margin of 50.0%, an 860 basis point improvement year-over-year, indicating enhanced operational efficiency.
• Substantial improvement in net loss, narrowing to $78,088, a 72% reduction from Q3 2024.
• Record pre-roll production of 209,600 units, an 81% increase year-over-year.
• Successful execution of the 2025 strategic plan, leading to demonstrable progress on revenue growth, distribution, and branded products.
• Ability to grow revenue and expand margins in a contracting cannabis market, demonstrating resilience and effective strategy.
• Diversified revenue streams through new brand launches (Doobskis, Dutch Blunts) gaining meaningful traction alongside the core Fresh Joints brand.
• Projected Q4 2025 revenue growth of 41%-66% year-over-year, with maintained 50% gross margins.
• Plans for two new company-owned brands to launch in Q4, targeting adjacent market segments.
• Evaluation of opportunities to replicate The Joint Company model in additional regulated markets, including Massachusetts and New York.

Negatives

• Despite significant improvement, the company still reported a GAAP net loss of $78,088 for the quarter.
• Total stockholders' deficit increased to $(2,595,508) as of September 30, 2025, from $(2,091,938) as of December 31, 2024.
• Current liabilities significantly exceed current assets ($1,872,581 vs. $196,832), indicating potential liquidity challenges.
• Cash balance decreased from $60,305 at December 31, 2024, to $16,743 at September 30, 2025.
• Interest expense increased to $(24,197) for the quarter and $(82,528) for the nine months ended September 30, 2025.

Risks

• Market conditions in the cannabis industry, which is described as "contracting" and one of the "toughest" in the country.
• Potential impacts from regulatory changes affecting the cannabis market.
• General risks described in Bespoke's filings with the SEC.

Future Outlook

For Q4 2025, Bespoke Extracts projects revenue between $425,000 and $500,000, representing a 41%-66% year-over-year increase, driven by continued demand for Fresh Joints and expansion of Doobskis and Dutch Blunts. The company expects to maintain approximately 50% blended gross margins across product lines through disciplined cost management and increased production throughput. Two new company-owned brands are slated for launch in Q4 to capture adjacent market segments, and the company is evaluating opportunities to replicate its model in additional regulated markets like Massachusetts and New York.

Management Comments

• "We're not chasing the market – we're building it." Hunter Garth, President.
• "Our Colorado business continues to prove that disciplined execution, brand trust, and smart manufacturing can win even in a contracting cannabis market." Hunter Garth, President.
• "Q3 was a turning point. We produced more pre-rolls, earned strong margins, and expanded our reach – all while holding the line on overhead costs." Hunter Garth, President.
• "Our 2025 strategic plan is delivering results, with demonstrable progress on revenue growth, distribution, and branded products." Michael Feinsod, Chairman and CEO.
• "Our flexibility to adapt to changing market conditions in our core pre-roll business has allowed us to succeed this year in Colorado, setting us apart from many other participants." Michael Feinsod, Chairman and CEO.
• "We've built each of our brands brick by brick in one of the toughest cannabis markets in the country." Hunter Garth, President.
• "The fact that we can grow revenue by approximately 69% while expanding margins in a shrinking market says everything about our team and our process. This is what operational excellence looks like – continual improvement through iteration, data, and pride in the craft." Hunter Garth, President.
• "These Q3 results are a testament to the resilience and innovation at the core of The Joint Company. Our team's focus on efficiency and quality has not only driven record growth but also positioned us for scalable expansion. We're excited about the pipeline ahead and confident in delivering sustained value to shareholders." Michael Feinsod, Chairman and CEO.
• "We're turning a single-state success story into a scalable blueprint. Our aim is simple – to control the pre-roll category through quality, efficiency, and culture. What started as a manufacturing facility in Aurora is now a system that can be replicated across markets." Hunter Garth, President.

Industry Context

The company operates in the regulated U.S. cannabis market, specifically in Colorado, which is described as a "contracting" and "toughest" market. Despite these challenging conditions, Bespoke Extracts (The Joint Company) has achieved significant revenue growth and margin expansion, suggesting outperformance relative to broader industry trends in its core market. Their focus on disciplined execution, brand trust, smart manufacturing, and cost control has allowed them to succeed where others might struggle. The company's strategy to replicate its model in other regulated markets like Massachusetts and New York indicates a belief in its scalable approach within the evolving national cannabis landscape.

Comparison to Industry Standards

• The company achieved 68.6% year-over-year revenue growth and expanded gross margins by 860 basis points in Q3 2025, which is notable given the "contracting cannabis market" in Colorado.
• Management explicitly states that their ability to grow revenue by approximately 69% while expanding margins in a shrinking market "sets us apart from many other participants" in the Colorado cannabis industry.
• No specific comparable companies or projects are named in the filing for direct quantitative comparison.

Related Party Transactions

• Advances related party: $66,872 as of September 30, 2025.
• Note payable related party: $849,500 as of September 30, 2025.

Stakeholder Impact

• Shareholders: The record financial performance, improved net loss, and positive future outlook suggest potential for increased shareholder value. Management explicitly states confidence in "delivering sustained value to shareholders." However, the continued net loss and significant liabilities could be a concern.
• Employees: The focus on "operational excellence" and "pride in the craft" suggests a positive environment for the team, with growth potentially leading to more opportunities.
• Customers: The emphasis on "quality" and "brand trust" for products like Fresh Joints, Doobskis, and Dutch Blunts indicates a commitment to customer satisfaction and expanding product offerings.
• Creditors: The significant current liabilities and notes payable, including related party notes, indicate a reliance on debt financing, which could be a concern for creditors despite improved operational performance.

Next Steps

• Launch two new company-owned brands in Q4 2025.
• Evaluate opportunities to replicate The Joint Company model in additional regulated markets, including Massachusetts and New York.
• Continue to drive demand for Fresh Joints and expand Doobskis and Dutch Blunts.
• Maintain approximately 50% blended gross margins across product lines.

Key Dates

Recommendation

While Bespoke Extracts demonstrated impressive operational improvements, record revenue growth, and significant margin expansion in a challenging market, the company still reports a net loss and faces substantial current liabilities relative to its cash position. The positive momentum and future expansion plans are encouraging, but the underlying financial structure, particularly the large stockholders' deficit and reliance on debt, warrants a cautious approach. A "hold" recommendation allows investors to observe if the company can sustain profitability and improve its balance sheet health while executing its expansion strategy.

Keywords

Cannabis, Pre-rolls, Extracts, Colorado, Financial Results, Q3 2025, Bespoke Extracts, The Joint Company, BSPK, Regulated Market, Manufacturing, Gross Margin, Revenue Growth